Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. | Nucleic Acids Res | 2024 | 37933841 | PubTator, text mining | PubMed |
| Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma. | Blood Cancer Discov | 2024 | 37767768 | PubTator, text mining | PubMed |
| New Biological Therapies for Multiple Myeloma. | Annu Rev Med | 2024 | 37729027 | PubTator, text mining | PubMed |
| Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma. | Genes Dis | 2024 | 37692509 | PubTator, text mining | PubMed |
| From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation. | Annu Rev Pharmacol Toxicol | 2024 | 37585660 | PubTator, text mining | PubMed |
| Ubiquitin-proteasome pathway-mediated regulation of the Bcl-2 family: effects and therapeutic approaches. | Haematologica | 2024 | 37584295 | PubTator, text mining | PubMed |
| The ubiquitin codes in cellular stress responses. | Protein Cell | 2024 | 37470788 | PubTator, text mining | PubMed |
| AZD7762 induces CRBN dependent BAG3 degradation through ubiquitin-proteasome pathway. | Anticancer Drugs | 2024 | 37449977 | PubTator, text mining | PubMed |
| Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials. | Haematologica | 2024 | 37439329 | PubTator, text mining | PubMed |
| Amyloid Precursor Protein: A Regulatory Hub in Alzheimer's Disease. | Aging Dis | 2024 | 37307834 | PubTator, text mining | PubMed |
| Integrative Role of the SALL4 Gene: From Thalidomide Embryopathy to Genetic Defects of the Upper Limb, Internal Organs, Cerebral Midline, and Pituitary. | Horm Res Paediatr | 2024 | 37285827 | PubTator, text mining | PubMed |
| Recent advances in targeted protein degraders as potential therapeutic agents. | Mol Divers | 2024 | 36790583 | PubTator, text mining | PubMed |
| How I treat multiple myeloma in geriatric patients. | Blood | 2024 | 36693134 | PubTator, text mining | PubMed |
| IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors. | Front Oncol | 2023 | 38344143 | PubTator, text mining | PubMed |
| Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer. | Pharmaceutics | 2023 | 38258065 | PubTator, text mining | PubMed |
| Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs. | Pharmaceutics | 2023 | 38258058 | PubTator, text mining | PubMed |
| Molecular Marvels: Small Molecules Paving the Way for Enhanced Gene Therapy. | Pharmaceuticals (Basel) | 2023 | 38256875 | PubTator, text mining | PubMed |
| Melatonin Prevents Alcohol- and Metabolic Dysfunction- Associated Steatotic Liver Disease by Mitigating Gut Dysbiosis, Intestinal Barrier Dysfunction, and Endotoxemia. | Antioxidants (Basel) | 2023 | 38247468 | PubTator, text mining | PubMed |
| An elevated systemic inflammation index is related to an inferior response to pomalidomide and dexamethasone treatment in patients with relapsed and refractory multiple myeloma. | Contemp Oncol (Pozn) | 2023 | 38239862 | PubTator, text mining | PubMed |
| Proteome-Wide Fragment-Based Ligand and Target Discovery. | Isr J Chem | 2023 | 38213795 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=25